Generic Drug Market Trends, Demand, Industry Size, Future Growth and Opportunities During 2021-2026
Generic Drug Market Trends, Demand, Industry Size, Future Growth and Opportunities During 2021-2026
Published by IMARC Services Private Limited
Posted on September 9, 2021
According to the latest report by IMARC Group, titled “Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″, the global generic drugs market size reached a value of US$ 386 Billion in 2020. Looking forward, the market value is projected to reach US$ 517 Billion by 2026, expanding at a CAGR of 4.9% during the forecast period (2021-2026). Generic drugs are identical to branded drugs in terms of safety, dosage, form, strength, quality, performance, characteristics, and route of administration. They have the same active ingredients, offer an equivalent therapeutic effect and are proven safe as the branded drug. They are also cost-effective as manufacturers do not have to invest in research and development (R&D) and marketing activities. At present, generic drugs are gaining immense popularity across the world.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The rising prevalence of chronic diseases, such as dyslipidemia, diabetes, hypertension, and metabolic syndrome, on account of sedentary lifestyles, hectic work schedules and changing dietary patterns, have increased the uptake of medicines across the world. This represents one of the primary factors facilitating the global generic drugs market growth. Additionally, the rising patent expiration of branded drugs, in confluence with increasing initiatives by governing authorities, is encouraging key manufacturers to introduce effective generic drugs, which, in turn, is significantly contributing to the market growth. For instance, seven hospitals and three philanthropies in the United States launched a generic drug company named Civica Rx in 2018 to address the shortage of drugs and the high cost of essential medication, producing fourteen short-supply, FDA-approved drugs.
The competitive landscape of the market has been examined, with some key players being Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited and Aspen Pharmacare Holdings Limited.
Breakup by Therapy Area:
Central Nervous System
Cardiovascular
Dermatology
Genitourinary/Hormonal
Respiratory
Rheumatology
Diabetes
Oncology
Others
Breakup by Drug Delivery:
Oral
Injectables
Dermal/Topical
Inhalers
Breakup by Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Regional Insights:
United States
China
Brazil
Germany
France
India
United Kingdom
Japan
Canada
Italy
Others
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US: IMARC Group 30 N Gould St, Ste R Sheridan, WY 82801, USA Website: www.imarcgroup.com Email: sales@imarcgroup.com USA: +1-631-791-1145 Follow us on twitter: @imarcglobal
According to the latest report by IMARC Group, titled “Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″, the global generic drugs market size reached a value of US$ 386 Billion in 2020. Looking forward, the market value is projected to reach US$ 517 Billion by 2026, expanding at a CAGR of 4.9% during the forecast period (2021-2026). Generic drugs are identical to branded drugs in terms of safety, dosage, form, strength, quality, performance, characteristics, and route of administration. They have the same active ingredients, offer an equivalent therapeutic effect and are proven safe as the branded drug. They are also cost-effective as manufacturers do not have to invest in research and development (R&D) and marketing activities. At present, generic drugs are gaining immense popularity across the world.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The rising prevalence of chronic diseases, such as dyslipidemia, diabetes, hypertension, and metabolic syndrome, on account of sedentary lifestyles, hectic work schedules and changing dietary patterns, have increased the uptake of medicines across the world. This represents one of the primary factors facilitating the global generic drugs market growth. Additionally, the rising patent expiration of branded drugs, in confluence with increasing initiatives by governing authorities, is encouraging key manufacturers to introduce effective generic drugs, which, in turn, is significantly contributing to the market growth. For instance, seven hospitals and three philanthropies in the United States launched a generic drug company named Civica Rx in 2018 to address the shortage of drugs and the high cost of essential medication, producing fourteen short-supply, FDA-approved drugs.
The competitive landscape of the market has been examined, with some key players being Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited and Aspen Pharmacare Holdings Limited.
Breakup by Therapy Area:
Central Nervous System
Cardiovascular
Dermatology
Genitourinary/Hormonal
Respiratory
Rheumatology
Diabetes
Oncology
Others
Breakup by Drug Delivery:
Oral
Injectables
Dermal/Topical
Inhalers
Breakup by Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Regional Insights:
United States
China
Brazil
Germany
France
India
United Kingdom
Japan
Canada
Italy
Others
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US: IMARC Group 30 N Gould St, Ste R Sheridan, WY 82801, USA Website: www.imarcgroup.com Email: sales@imarcgroup.com USA: +1-631-791-1145 Follow us on twitter: @imarcglobal